

## Executive Summary of Collaborative Working Project.

**Astellas Pharma Ltd and Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust.**

**Prostate Cancer Patient Reported Outcome Measures (PROM's) through Non-Medical Prescriber (NMP) patient-initiated follow-up (PIFU).**

**September 2024**

### **Objective:**

To develop an NMP led clinic PIFU virtual toolkit through PROM's, via collaborative working between Astellas Pharma Ltd, Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust and Evergreen Health Solutions Ltd, that allows stable prostate cancer patients to complete questionnaires about their current well-being and health status without the need for a face-to-face appointment.

### **Summary:**

New Prostate Cancer cases account for 26% of all new cancer cases in males with 48,500 patients diagnosed every year, this creates a burden on capacity for the NHS within Prostate Cancer clinics in times of restricted NHS budgets.

The Prostate Cancer NMP PIFU programme will enable cancer centres to work in partnership with Astellas/Evergreen Health Solutions Ltd to develop the toolkit via collaborative working. Patients monitoring their well-being via PIFU will involve patients more in their own care and remove unnecessary face to face appointments and thus relieving pressures on Prostate Cancer services.

Astellas are committed to supporting the NHS within Prostate Cancer. By working in partnership, Astellas are at the forefront of driving innovation and change for the positive benefit of patients and assisting the NHS in delivering high standards of care. Working in partnership between Astellas, Evergreen Health Solutions Ltd, and cancer centres, pooling of joint expertise to develop and validate the toolkit, will support health professionals in their desire to improve patient well-being.

### **Benefits of Project**

Patients	<ul style="list-style-type: none"><li>• PIFU allows patients to be involved in monitoring their own well-being.</li><li>• Reduction in the need for hospital visits, so they can be monitored at home, reducing any anxiety about visiting hospital.</li><li>• No need to wait for appointments for PIFU patients.</li><li>• May lead to improved patient experiences.</li></ul>
NHS	<ul style="list-style-type: none"><li>• Greater than 25% improved follow-up capacity within Prostate cancer clinics.</li><li>• Improvement in baseline metrics such as waiting times and other such national targets.</li><li>• An efficient service will lead to a more sustainable service.</li><li>• May lead to improved patient satisfaction of the service they receive.</li><li>• May lead to staff satisfaction and retention.</li></ul>

Astellas Pharma Ltd	<ul style="list-style-type: none"><li>• Recognition of Astellas offering value added services that benefit NHS Prostate Cancer services.</li><li>• Development of relationships with cancer centres through working in partnership to solve unmet needs.</li><li>• With expected &gt;25% of NMP patient being managed through PIFU, it is expected case load capacity will increase leading to more throughput of patients which may lead to a benefit of increased use of Astellas products.</li><li>• Enhancing expertise in-house.</li></ul>
------------------------	---